Apyx Medical Corp — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
CEO Charles D. Goodwin II and CFO Matthew Hill certified the Q2 2026 10-Q (period ended June 30, 2026) filed August 6, 2026. Both officers affirmed financial statement accuracy, effectiveness of disclosure controls and internal controls over financial reporting, and absence of material weaknesses or fraud. No operational, financial, or strategic changes were disclosed in these certification exhibits.
Why this rating
Boilerplate SOX compliance exhibits with no substantive business information, financial metrics, or material events. Routine quarterly filing requirement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.